Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
semaglutide
Biotech
A look at the R&D landscape in obesity, led by GLP-1s
If you’re feeling like the obesity pipeline filled up overnight, you’re not alone. A new analysis from IQVIA takes a look at the drugs in development.
Annalee Armstrong
,
Gabrielle Masson
Mar 19, 2024 8:00am
Another win for Novo in obesity as early oral med beats Wegovy
Mar 7, 2024 9:27am
Novo Nordisk advances obesity pill as R&D spend skyrockets 35%
Jan 31, 2024 9:44am
GLP-1 drug hydrogels could reduce shots to 3 times a year
Nov 28, 2023 11:30am
Fractyl's GLP-1 obesity gene therapy outdoes semaglutide—in mice
Oct 4, 2023 4:24pm
Blood-brain barrier no barrier to diabetes drugs in Alzheimer's
Oct 27, 2022 3:10pm